< em > USH2A < /em > mutation and specific driver mutation subtypes are associated with clinical efficacy of immune checkpoint inhibitors in lung cancer
This study aimed to identify subtypes of genomic variants associated with the efficacy of immune checkpoint inhibitors (ICIs) by conducting systematic literature search in electronic databases up to May 31, 2021. The main outcomes including overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and durable clinical benefit (DCB) were correlated with tumor genomic features. A total of 1546 lung cancer patients with available genomic variation data were included from 14 studies. The Kirsten rat sarcoma viral oncogene homolog G12C (KRASG12C) mutation combined with tumor protein P53 (TP53) mutat...
Source: J Zhejiang Univ Sci ... - February 8, 2023 Category: Science Authors: Dexin Yang Yuqin Feng Haohua Lu Kelie Chen Jinming Xu Peiwei Li Tianru Wang Dajing Xia Yihua Wu Source Type: research
< em > USH2A < /em > mutation and specific driver mutation subtypes are associated with clinical efficacy of immune checkpoint inhibitors in lung cancer
This study aimed to identify subtypes of genomic variants associated with the efficacy of immune checkpoint inhibitors (ICIs) by conducting systematic literature search in electronic databases up to May 31, 2021. The main outcomes including overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and durable clinical benefit (DCB) were correlated with tumor genomic features. A total of 1546 lung cancer patients with available genomic variation data were included from 14 studies. The Kirsten rat sarcoma viral oncogene homolog G12C (KRASG12C) mutation combined with tumor protein P53 (TP53) mutat...
Source: J Zhejiang Univ Sci ... - February 8, 2023 Category: Science Authors: Dexin Yang Yuqin Feng Haohua Lu Kelie Chen Jinming Xu Peiwei Li Tianru Wang Dajing Xia Yihua Wu Source Type: research
< em > USH2A < /em > mutation and specific driver mutation subtypes are associated with clinical efficacy of immune checkpoint inhibitors in lung cancer
This study aimed to identify subtypes of genomic variants associated with the efficacy of immune checkpoint inhibitors (ICIs) by conducting systematic literature search in electronic databases up to May 31, 2021. The main outcomes including overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and durable clinical benefit (DCB) were correlated with tumor genomic features. A total of 1546 lung cancer patients with available genomic variation data were included from 14 studies. The Kirsten rat sarcoma viral oncogene homolog G12C (KRASG12C) mutation combined with tumor protein P53 (TP53) mutat...
Source: J Zhejiang Univ Sci ... - February 8, 2023 Category: Science Authors: Dexin Yang Yuqin Feng Haohua Lu Kelie Chen Jinming Xu Peiwei Li Tianru Wang Dajing Xia Yihua Wu Source Type: research
< em > USH2A < /em > mutation and specific driver mutation subtypes are associated with clinical efficacy of immune checkpoint inhibitors in lung cancer
This study aimed to identify subtypes of genomic variants associated with the efficacy of immune checkpoint inhibitors (ICIs) by conducting systematic literature search in electronic databases up to May 31, 2021. The main outcomes including overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and durable clinical benefit (DCB) were correlated with tumor genomic features. A total of 1546 lung cancer patients with available genomic variation data were included from 14 studies. The Kirsten rat sarcoma viral oncogene homolog G12C (KRASG12C) mutation combined with tumor protein P53 (TP53) mutat...
Source: J Zhejiang Univ Sci ... - February 8, 2023 Category: Science Authors: Dexin Yang Yuqin Feng Haohua Lu Kelie Chen Jinming Xu Peiwei Li Tianru Wang Dajing Xia Yihua Wu Source Type: research
< em > USH2A < /em > mutation and specific driver mutation subtypes are associated with clinical efficacy of immune checkpoint inhibitors in lung cancer
This study aimed to identify subtypes of genomic variants associated with the efficacy of immune checkpoint inhibitors (ICIs) by conducting systematic literature search in electronic databases up to May 31, 2021. The main outcomes including overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and durable clinical benefit (DCB) were correlated with tumor genomic features. A total of 1546 lung cancer patients with available genomic variation data were included from 14 studies. The Kirsten rat sarcoma viral oncogene homolog G12C (KRASG12C) mutation combined with tumor protein P53 (TP53) mutat...
Source: J Zhejiang Univ Sci ... - February 8, 2023 Category: Science Authors: Dexin Yang Yuqin Feng Haohua Lu Kelie Chen Jinming Xu Peiwei Li Tianru Wang Dajing Xia Yihua Wu Source Type: research
< em > USH2A < /em > mutation and specific driver mutation subtypes are associated with clinical efficacy of immune checkpoint inhibitors in lung cancer
This study aimed to identify subtypes of genomic variants associated with the efficacy of immune checkpoint inhibitors (ICIs) by conducting systematic literature search in electronic databases up to May 31, 2021. The main outcomes including overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and durable clinical benefit (DCB) were correlated with tumor genomic features. A total of 1546 lung cancer patients with available genomic variation data were included from 14 studies. The Kirsten rat sarcoma viral oncogene homolog G12C (KRASG12C) mutation combined with tumor protein P53 (TP53) mutat...
Source: J Zhejiang Univ Sci ... - February 8, 2023 Category: Science Authors: Dexin Yang Yuqin Feng Haohua Lu Kelie Chen Jinming Xu Peiwei Li Tianru Wang Dajing Xia Yihua Wu Source Type: research
< em > USH2A < /em > mutation and specific driver mutation subtypes are associated with clinical efficacy of immune checkpoint inhibitors in lung cancer
This study aimed to identify subtypes of genomic variants associated with the efficacy of immune checkpoint inhibitors (ICIs) by conducting systematic literature search in electronic databases up to May 31, 2021. The main outcomes including overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and durable clinical benefit (DCB) were correlated with tumor genomic features. A total of 1546 lung cancer patients with available genomic variation data were included from 14 studies. The Kirsten rat sarcoma viral oncogene homolog G12C (KRASG12C) mutation combined with tumor protein P53 (TP53) mutat...
Source: J Zhejiang Univ Sci ... - February 8, 2023 Category: Science Authors: Dexin Yang Yuqin Feng Haohua Lu Kelie Chen Jinming Xu Peiwei Li Tianru Wang Dajing Xia Yihua Wu Source Type: research
< em > USH2A < /em > mutation and specific driver mutation subtypes are associated with clinical efficacy of immune checkpoint inhibitors in lung cancer
This study aimed to identify subtypes of genomic variants associated with the efficacy of immune checkpoint inhibitors (ICIs) by conducting systematic literature search in electronic databases up to May 31, 2021. The main outcomes including overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and durable clinical benefit (DCB) were correlated with tumor genomic features. A total of 1546 lung cancer patients with available genomic variation data were included from 14 studies. The Kirsten rat sarcoma viral oncogene homolog G12C (KRASG12C) mutation combined with tumor protein P53 (TP53) mutat...
Source: J Zhejiang Univ Sci ... - February 8, 2023 Category: Science Authors: Dexin Yang Yuqin Feng Haohua Lu Kelie Chen Jinming Xu Peiwei Li Tianru Wang Dajing Xia Yihua Wu Source Type: research
< em > USH2A < /em > mutation and specific driver mutation subtypes are associated with clinical efficacy of immune checkpoint inhibitors in lung cancer
This study aimed to identify subtypes of genomic variants associated with the efficacy of immune checkpoint inhibitors (ICIs) by conducting systematic literature search in electronic databases up to May 31, 2021. The main outcomes including overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and durable clinical benefit (DCB) were correlated with tumor genomic features. A total of 1546 lung cancer patients with available genomic variation data were included from 14 studies. The Kirsten rat sarcoma viral oncogene homolog G12C (KRASG12C) mutation combined with tumor protein P53 (TP53) mutat...
Source: J Zhejiang Univ Sci ... - February 8, 2023 Category: Science Authors: Dexin Yang Yuqin Feng Haohua Lu Kelie Chen Jinming Xu Peiwei Li Tianru Wang Dajing Xia Yihua Wu Source Type: research
< em > USH2A < /em > mutation and specific driver mutation subtypes are associated with clinical efficacy of immune checkpoint inhibitors in lung cancer
This study aimed to identify subtypes of genomic variants associated with the efficacy of immune checkpoint inhibitors (ICIs) by conducting systematic literature search in electronic databases up to May 31, 2021. The main outcomes including overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and durable clinical benefit (DCB) were correlated with tumor genomic features. A total of 1546 lung cancer patients with available genomic variation data were included from 14 studies. The Kirsten rat sarcoma viral oncogene homolog G12C (KRASG12C) mutation combined with tumor protein P53 (TP53) mutat...
Source: J Zhejiang Univ Sci ... - February 8, 2023 Category: Science Authors: Dexin Yang Yuqin Feng Haohua Lu Kelie Chen Jinming Xu Peiwei Li Tianru Wang Dajing Xia Yihua Wu Source Type: research
< em > USH2A < /em > mutation and specific driver mutation subtypes are associated with clinical efficacy of immune checkpoint inhibitors in lung cancer
This study aimed to identify subtypes of genomic variants associated with the efficacy of immune checkpoint inhibitors (ICIs) by conducting systematic literature search in electronic databases up to May 31, 2021. The main outcomes including overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and durable clinical benefit (DCB) were correlated with tumor genomic features. A total of 1546 lung cancer patients with available genomic variation data were included from 14 studies. The Kirsten rat sarcoma viral oncogene homolog G12C (KRASG12C) mutation combined with tumor protein P53 (TP53) mutat...
Source: J Zhejiang Univ Sci ... - February 8, 2023 Category: Science Authors: Dexin Yang Yuqin Feng Haohua Lu Kelie Chen Jinming Xu Peiwei Li Tianru Wang Dajing Xia Yihua Wu Source Type: research
< em > USH2A < /em > mutation and specific driver mutation subtypes are associated with clinical efficacy of immune checkpoint inhibitors in lung cancer
This study aimed to identify subtypes of genomic variants associated with the efficacy of immune checkpoint inhibitors (ICIs) by conducting systematic literature search in electronic databases up to May 31, 2021. The main outcomes including overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and durable clinical benefit (DCB) were correlated with tumor genomic features. A total of 1546 lung cancer patients with available genomic variation data were included from 14 studies. The Kirsten rat sarcoma viral oncogene homolog G12C (KRASG12C) mutation combined with tumor protein P53 (TP53) mutat...
Source: J Zhejiang Univ Sci ... - February 8, 2023 Category: Science Authors: Dexin Yang Yuqin Feng Haohua Lu Kelie Chen Jinming Xu Peiwei Li Tianru Wang Dajing Xia Yihua Wu Source Type: research
< em > USH2A < /em > mutation and specific driver mutation subtypes are associated with clinical efficacy of immune checkpoint inhibitors in lung cancer
This study aimed to identify subtypes of genomic variants associated with the efficacy of immune checkpoint inhibitors (ICIs) by conducting systematic literature search in electronic databases up to May 31, 2021. The main outcomes including overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and durable clinical benefit (DCB) were correlated with tumor genomic features. A total of 1546 lung cancer patients with available genomic variation data were included from 14 studies. The Kirsten rat sarcoma viral oncogene homolog G12C (KRASG12C) mutation combined with tumor protein P53 (TP53) mutat...
Source: J Zhejiang Univ Sci ... - February 8, 2023 Category: Science Authors: Dexin Yang Yuqin Feng Haohua Lu Kelie Chen Jinming Xu Peiwei Li Tianru Wang Dajing Xia Yihua Wu Source Type: research
< em > USH2A < /em > mutation and specific driver mutation subtypes are associated with clinical efficacy of immune checkpoint inhibitors in lung cancer
This study aimed to identify subtypes of genomic variants associated with the efficacy of immune checkpoint inhibitors (ICIs) by conducting systematic literature search in electronic databases up to May 31, 2021. The main outcomes including overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and durable clinical benefit (DCB) were correlated with tumor genomic features. A total of 1546 lung cancer patients with available genomic variation data were included from 14 studies. The Kirsten rat sarcoma viral oncogene homolog G12C (KRASG12C) mutation combined with tumor protein P53 (TP53) mutat...
Source: J Zhejiang Univ Sci ... - February 8, 2023 Category: Science Authors: Dexin Yang Yuqin Feng Haohua Lu Kelie Chen Jinming Xu Peiwei Li Tianru Wang Dajing Xia Yihua Wu Source Type: research
< em > USH2A < /em > mutation and specific driver mutation subtypes are associated with clinical efficacy of immune checkpoint inhibitors in lung cancer
This study aimed to identify subtypes of genomic variants associated with the efficacy of immune checkpoint inhibitors (ICIs) by conducting systematic literature search in electronic databases up to May 31, 2021. The main outcomes including overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and durable clinical benefit (DCB) were correlated with tumor genomic features. A total of 1546 lung cancer patients with available genomic variation data were included from 14 studies. The Kirsten rat sarcoma viral oncogene homolog G12C (KRASG12C) mutation combined with tumor protein P53 (TP53) mutat...
Source: J Zhejiang Univ Sci ... - February 8, 2023 Category: Science Authors: Dexin Yang Yuqin Feng Haohua Lu Kelie Chen Jinming Xu Peiwei Li Tianru Wang Dajing Xia Yihua Wu Source Type: research
